International archives of allergy and immunology · 2025
Hereditary Alpha Tryptasemia: Survey of Concomitant Genetic Testing.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Butterfield Joseph H, Butterfield Joseph H, Bhasin Arveen K, Ishmael Leah L, Squire Jacqueline D
Аннотация
INTRODUCTION: Hereditary alpha tryptasemia (HαT) affects 4-6% of the general population. Inherited as a Mendelian dominant, HαT has a variable phenotypic expression. Many patients have no obvious symptoms. There is a dearth of reports of possible co-inheritance of other genetic abnormalities.
METHODS: We examined records of 69 Mayo Clinic patients with HαT for the results of any additional genetic studies obtained during routine or focused evaluations. Clinical records of patients evaluated for baseline tryptase values >8 ng/mL testing positive for the TPSAB1 mutation were reviewed. Screening genetic tests obtained during standard care and/or for evaluation of clinical symptoms were recorded as well as inciting symptoms that led to tryptase determination, the serum tryptase level, alpha- and beta-tryptase gene copy numbers, and the urinary mast cell mediator metabolites.
RESULTS: Bone marrow biopsies for systemic mastocytosis and the presence of either a KIT Asp816Val, or Janus kinase 2 Val617Phe mutation were negative. Genetic tests were diverse and included nearly 1,000 suspect genes in 1 case and one to several hundred in others. There was no genetic testing in 19 patients and normal genetic test findings in 37 patients. A group of 8 patients showed at least one genetic abnormality and in a group of 5 patients, both normal and abnormal genetic findings were present. There was no clustering of genetic tests or relation to the inciting symptoms.
CONCLUSION: Genetic testing, often extensive, was obtained in 73% of these HαT patients. Most of these results were normal and did not suggest the presence of a concomitant genetic disorder.
METHODS: We examined records of 69 Mayo Clinic patients with HαT for the results of any additional genetic studies obtained during routine or focused evaluations. Clinical records of patients evaluated for baseline tryptase values >8 ng/mL testing positive for the TPSAB1 mutation were reviewed. Screening genetic tests obtained during standard care and/or for evaluation of clinical symptoms were recorded as well as inciting symptoms that led to tryptase determination, the serum tryptase level, alpha- and beta-tryptase gene copy numbers, and the urinary mast cell mediator metabolites.
RESULTS: Bone marrow biopsies for systemic mastocytosis and the presence of either a KIT Asp816Val, or Janus kinase 2 Val617Phe mutation were negative. Genetic tests were diverse and included nearly 1,000 suspect genes in 1 case and one to several hundred in others. There was no genetic testing in 19 patients and normal genetic test findings in 37 patients. A group of 8 patients showed at least one genetic abnormality and in a group of 5 patients, both normal and abnormal genetic findings were present. There was no clustering of genetic tests or relation to the inciting symptoms.
CONCLUSION: Genetic testing, often extensive, was obtained in 73% of these HαT patients. Most of these results were normal and did not suggest the presence of a concomitant genetic disorder.